About

Targeted Therapeutics for Cancer and Ophthalmology

Management Team

Charles P. Theuer, M.D., Ph.D.
President and CEO
Dr. Theuer has served as our President, Chief Executive Officer and a member of our board of directors since July 2006. From 2004 to 2006, Dr. Theuer was the Chief Medical Officer and Vice President of Clinical Development at TargeGen, Inc., a biotechnology company, where he led the development of small molecule kinase inhibitors in oncology, ophthalmology and cardiovascular disease. Prior to joining TargeGen, Inc., Dr. Theuer was Director of Clinical Oncology at Pfizer, Inc., a pharmaceutical corporation, from 2003 to 2004. At Pfizer, Dr. Theuer led the clinical development of Sutent® in kidney cancer; Sutent® was approved by the U.S. Food and Drug Administration in 2006 for the treatment of advanced kidney cancer. Dr. Theuer has also held senior positions at IDEC Pharmaceuticals Corp. from 2002 to 2003 and at the National Cancer Institute from 1991 to 1993. In addition, he has held academic positions at the University of California, Irvine, where he was Assistant Professor in the Division of Surgical Oncology and Department of Medicine. Dr. Theuer received a B.S. from the Massachusetts Institute of Technology, an M.D. from the University of California, San Francisco, and a Ph.D. from the University of California, Irvine. He completed a general surgery residency program at Harbor-UCLA Medical Center and was board certified in general surgery in 1997.  Dr. Theuer’s previous research involved immunotoxin and cancer vaccine development, translational work in cancer patients, and gastrointestinal cancer epidemiology.

Bonne Adams, M.B.A.
Senior Vice President, Clinical Operations
Ms. Adams joined us as our Vice President of Clinical Operations in August 2006 and was promoted to Senior Vice President of Clinical Operations in July 2014. Prior to joining us, Ms. Adams was a Manager of Clinical Operations at Pfizer, Inc., a pharmaceutical corporation, from 2004 to 2006 and at Biogen Idec, Inc., a biotechnology company, from 2002 to 2004. Ms. Adams managed clinical trials at Pfizer that contributed to the 2006 approval of Sutent® in renal cell carcinoma and gastrointestinal stromal tumors, and she managed clinical trials at Biogen Idec that fulfilled post-approval commitments for Zevalin® and Rituxan®. Ms. Adams has managed both early and late-stage oncology studies of small molecules as well as biologics in the areas of lymphoma, lung, colorectal, ovarian, kidney, sarcoma and breast cancers. From 2000 to 2002, she managed non-oncology programs at Quintiles Inc., a service provider for biopharmaceutical and health sciences companies, including studies in the areas of allergy and pulmonary disease. Ms. Adams received a B.A. in Kinesiology and Biology from the University of Colorado and an M.B.A. in Technology Management from The University of Phoenix.

Suzy Benedict, M.S.
Vice President, Regulatory Affairs
Ms. Benedict joined us as our Director of Regulatory Affairs in 2007 and was promoted to Vice President of Regulatory Affairs in January 2014. Ms. Benedict previously held positions in Regulatory Chemistry, Manufacturing and Controls (CMC) at Pfizer, Inc. and Amylin Pharmaceuticals, Inc. At Pfizer, she led the Regulatory CMC activities for the approval of Viracept® Tablets, 625 mg and played a key role in the global approvals for Macugen®. She began her pharmaceutical career at Agouron Pharmaceuticals in Medicinal Chemistry synthesizing VEGF inhibitors. Ms. Benedict has led the Regulatory CMC activities on chemical and pharmaceutical development teams from compound identification through commercialization and has experience with small molecule, peptide, oligonucleotide and protein products spanning a wide range of therapeutic areas. Ms. Benedict received a B.A. from the University of California, Santa Barbara and a M.S. in Chemistry from San Diego State University.

Patricia Bitar, C.P.A.
Chief Financial Officer
Ms. Bitar joined us as our Chief Financial Officer in September 2014. Prior to joining us, Ms. Bitar served in roles of increasing responsibility at NuVasive, Inc., a medical device company, serving most recently as Vice President and Corporate Controller from April 2011 to April 2014 and as the Senior Director of Financial Reporting from November 2009 to March 2011. From 2008 to October 2009 and during various periods of 1998 to 2006, Ms. Bitar provided independent financial consulting for a variety of companies, primarily in the biotechnology and electronics industries. From 2006 to 2008, Ms. Bitar served as the Corporate Controller at Orexigen Therapeutics, Inc., a biopharmaceutical company, where she was also the Senior Director of Financial Reporting from 2007 to 2008 and the Director of Financial Reporting from 2006 to 2007. From 1984 to 1991 and 1994 to 1998, she worked in the Audit Department at Ernst & Young, where from 1988, she served as a Senior Audit Manager, working primarily with clients in the technology and biotechnology industries. Ms. Bitar is a certified public accountant and received an M.A.I.S. from the University of West Florida and a B.S. in Business Administration (Accounting) from Old Dominion University.

Jennifer Ellis
Vice President, Quality Assurance
Ms. Ellis joined us as our Vice President of Quality Assurance in August 2014. Prior to joining us,  Ms. Ellis was Vice President of Quality Assurance at Trius Therapeutics, Inc. (acquired by Cubist Pharmaceuticals, Inc.) where she led the GxP Quality activities for development and commercialization of SivextroTM. SivextroTM was approved by the U.S Food and Drug Administration in June 2014. She started her career as an analytical chemist at Alliance Pharmaceuticals, then moved to leading analytical and CMC project teams at Pfizer, Inc.. In her career she has led CMC and Quality groups in the development of compounds in a variety of therapeutic areas. Ms. Ellis received a B.A. in Chemistry from the University of Delaware.

Laurence Gamelin, M.D., Ph.D.
Vice President, Pharmacovigilance and Safety
Dr. Gamelin joined us as our Vice President of Pharmacovigilance and Safety in October 2016. Previously, Dr. Gamelin was Executive Director of Safety at Ionis Pharmaceuticals from March 2015 to October 2016. At Ionis, Dr. Gamelin was the primary safety representative and led the safety activities for several antisense oligonucleotide (ASO) investigational therapies such as nusinersen, developed in partnership with Biogen and recently submitted to the FDA for the treatment of Spinal Muscular Atrophy in infants and children. Prior to Ionis, Dr. Gamelin was with Amgen and was Global Safety Officer. At Amgen, she led the safety activities for different marketed drugs and co-led the registrational submission of ivabradine (Corlanor®). Prior to Amgen, Dr. Gamelin was International Project Manager at Servier. Dr. Gamelin held academic positions in the University Hospital of Angers, France, where she was Associate Head of Poison Control Center and Assistant Professor in Clinical Toxicology. Dr. Gamelin was a member of expert advisory groups for Government Agencies for pharmacovigilance, toxicovigilance, evaluation of biocidal dossiers for marketing authorization, and preparedness for bioterrorism and major disasters. Her clinical research activity was in clinical toxicology and her bench research activity focused on mechanisms of drug neurotoxicity, resulting in international peer-reviewed publications, 2 international patents and Merritt Awards by the American Association for Cancer Research. Dr. Gamelin received an M.D. from the University of Angers, France, and a Ph.D. in Pharmaco-Toxicology from the National Natural History Museum and Paris-University 7, in France.

Casey Logan, M.B.A.
Chief Business Officer
Mr. Logan has served as our Chief Business Officer since February 2013. Prior to joining us, Mr. Logan was the Senior Vice President, Corporate Development at RuiYi, Inc. (formerly Anaphore Inc.), a biotechnology company, from January 2011 to February 2013. From 2007 to December 2010, Mr. Logan served as the Vice President, Corporate Development & Strategic Planning at Anadys Pharmaceuticals, Inc. (acquired by Roche), a biopharmaceutical company. From 2001 to 2007, he was with Eli Lilly and Company, a pharmaceutical company, in Indianapolis, Indiana, in the corporate business development group. Prior to joining Eli Lilly and Company, Mr. Logan was an officer in the U.S. Naval Nuclear Propulsion Program from 1993 to 1999. During his career, Mr. Logan has led transactions in both in-licensing and out-licensing of assets across a range of therapeutic areas, including the creation of two start-up companies. Mr. Logan received an M.B.A. from the Kellogg School of Management at Northwestern University and a B.S.E. in chemical engineering from the University of Michigan.

Sharon Real, Ph.D.
Senior Vice President, Product Development
Dr. Real joined us as our Vice President of Product Development in October 2006 and was promoted to Senior Vice President of Product Development in July 2014. Prior to joining us, Dr. Real served in roles of increasing responsibility at Pfizer, Inc., a pharmaceutical corporation, from 2000 to 2006, culminating in the position of Director of Regulatory Chemistry, Manufacturing and Controls. Before that, Dr. Real was Manager, Technical Operations at Ligand Pharmaceuticals Incorporated, a pharmaceutical company, from 1999 to 2000. From 1994 to 1999, Dr. Real served in various positions at Agouron Pharmaceuticals, Inc., a biotechnology company, most recently as Manager of Regulatory Chemistry, Manufacturing and Controls. From 1991 to 1994 she was in Chemical Process Research at Bristol-Myers Squibb Co., a global biopharmaceutical company. Dr. Real’s responsibilities have included leading chemical and pharmaceutical development teams from compound identification through commercialization. Dr. Real received a B.S. in Chemistry from Stanford University and a Ph.D. in Organic Chemistry from the University of California, Los Angeles.